Abstract
The specificity of drug targets is a great challenge in the pharma-proteomics field of cancer biology. In particular, bioinformatics methods based on complex networks and Gene Ontologies (GOs) are very useful in this area. This work reviews some bioinformatics concepts and previous studies related to Colorectal Cancer (CRC) research using GOs, complex networks, and related methods. Also, we report new results mapping natural compounds on potential drug target CRC network using GOs. The literature mining along with OMIM database gives the details of diseased genes which are further subjected to design a well connected gene regulatory network for cancer. The resultant network is then extrapolated to proteomics level to sort out the genes only expressed in the specific cancer types. The network is statistically analyzed and represented by the graphical interpretation to encounter the hub nodes and their locally parsed neighbors, ligands multi-receptor docking, and the propensity of drug targets in hub nodes and related sub-networks.
Keywords: Chemo preventive drugs, systems biology, mapping, colon cancer, gene ontology, Open Biomedical Ontologies, Colorectal Cancer, Kyoto Encyclopedia of Genes and Genomes, Unified Medical Language System, National Center for Biomedical Ontology
Current Bioinformatics
Title: Complex Network and Gene Ontology in Pharmacology Approaches:Mapping Natural Compounds on Potential Drug Target Colon Cancer Network
Volume: 6 Issue: 1
Author(s): Biplab Bhattacharjee, R. M. Jayadeepa, Usha Talambedu, Sanghita Banerjee, Jayadev Joshi, Jilu Princy Mole, Joshua Samuel and Sushil Kumar Middha
Affiliation:
Keywords: Chemo preventive drugs, systems biology, mapping, colon cancer, gene ontology, Open Biomedical Ontologies, Colorectal Cancer, Kyoto Encyclopedia of Genes and Genomes, Unified Medical Language System, National Center for Biomedical Ontology
Abstract: The specificity of drug targets is a great challenge in the pharma-proteomics field of cancer biology. In particular, bioinformatics methods based on complex networks and Gene Ontologies (GOs) are very useful in this area. This work reviews some bioinformatics concepts and previous studies related to Colorectal Cancer (CRC) research using GOs, complex networks, and related methods. Also, we report new results mapping natural compounds on potential drug target CRC network using GOs. The literature mining along with OMIM database gives the details of diseased genes which are further subjected to design a well connected gene regulatory network for cancer. The resultant network is then extrapolated to proteomics level to sort out the genes only expressed in the specific cancer types. The network is statistically analyzed and represented by the graphical interpretation to encounter the hub nodes and their locally parsed neighbors, ligands multi-receptor docking, and the propensity of drug targets in hub nodes and related sub-networks.
Export Options
About this article
Cite this article as:
Bhattacharjee Biplab, M. Jayadeepa R., Talambedu Usha, Banerjee Sanghita, Joshi Jayadev, Princy Mole Jilu, Samuel Joshua and Kumar Middha Sushil, Complex Network and Gene Ontology in Pharmacology Approaches:Mapping Natural Compounds on Potential Drug Target Colon Cancer Network, Current Bioinformatics 2011; 6 (1) . https://dx.doi.org/10.2174/157489311795222400
DOI https://dx.doi.org/10.2174/157489311795222400 |
Print ISSN 1574-8936 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-392X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition
Current Genomics Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Current Gene Therapy The Mutator Phenotype in Cancer: Molecular Mechanisms and Targeting Strategies
Current Drug Targets Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Current Medicinal Chemistry Cancer Metastasis: Characterization and Identification of the Behavior of Metastatic Tumor Cells and the Cell Adhesion Molecules, including Carbohydrates
Current Drug Targets - Cardiovascular & Hematological Disorders Mechanism of Drug Sensitivity and Resistance in Melanoma
Current Cancer Drug Targets Update on the Development of microRNA and siRNA Molecules as Regulators of Cell Physiology
Recent Patents on DNA & Gene Sequences ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Current Medicinal Chemistry T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease
Current Signal Transduction Therapy Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype
Current Cancer Drug Targets Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances
Current Pharmaceutical Biotechnology The Interplay between the Gut Immune System and Microbiota in Health and Disease: Nutraceutical Intervention for Restoring Intestinal Homeostasis
Current Pharmaceutical Design Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome
Current Genomics Synthesis, Characterization, Antimicrobial and Anticancer Studies of Metal Complexes of 2-methoxy-4-((3-methylpyridin-2-ylimino)methyl)phenol
Mini-Reviews in Medicinal Chemistry Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Current Cancer Drug Targets